Kairos Pharma (NYSEAMERICAN:KAPA) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) posted its earnings results on Friday. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.04, FiscalAI reports.

Kairos Pharma Trading Down 5.6%

NYSEAMERICAN KAPA traded down $0.03 on Friday, hitting $0.45. The company’s stock had a trading volume of 12,561 shares, compared to its average volume of 91,918. Kairos Pharma has a 52-week low of $0.42 and a 52-week high of $7.28. The company’s 50-day simple moving average is $1.08 and its 200 day simple moving average is $2.80. The firm has a market cap of $1.54 million, a P/E ratio of -0.23 and a beta of 1.85.

About Kairos Pharma

(Get Free Report)

Kairos Pharma, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies designed to address immune suppression and treatment resistance within the tumor microenvironment. The company’s research is centered on immuno-oncology approaches intended to improve the body’s ability to recognize and attack cancer cells. Kairos Pharma is developing a pipeline of investigational therapies, including antibody-based and small-molecule programs aimed at biological pathways associated with tumor growth, immune evasion and resistance to existing treatments.

Read More

Earnings History for Kairos Pharma (NYSEAMERICAN:KAPA)

Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.